Sign in

    Yingqi Peng

    Research Analyst at UBS

    Yingqi Peng is an Equity Research Analyst at UBS, specializing in healthcare sector research with a focus on biotechnology companies. Notably, Peng has covered companies such as I-Mab and has participated in earnings calls to analyze and provide investment insights for this firm. While detailed historical career data, quantitative performance metrics, and professional credential information are not publicly available, Peng's role at UBS demonstrates expertise in the healthcare and biotech research space. Prior roles, recognition, and licensing credentials have not been disclosed in available sources.

    Yingqi Peng's questions to I-Mab (IMAB) leadership

    Yingqi Peng's questions to I-Mab (IMAB) leadership • Q4 2021

    Question

    Yingqi Peng asked for the latest update on the BLA submission for TJ202 (felzartamab) in China, questioning the difference between filing as an imported versus a domestic product and the expected timeline for completion.

    Answer

    Jingwu Zang, Founder, Chairman and Acting CEO, explained that the BLA submission for felzartamab was slightly delayed for two reasons. First, the company is in discussions with China's CDE regarding a new conditional approval policy. Second, they decided to submit a new BLA package that includes a localized manufacturing plan to significantly reduce costs and enhance commercial competitiveness. Dr. Zang stated they hope to submit the new BLA package soon within 2022.

    Ask Fintool Equity Research AI